285 related articles for article (PubMed ID: 28851363)
1. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
[TBL] [Abstract][Full Text] [Related]
2. In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; Ruiz-Pino F; Guler I; Camargo A; Anglada FJ; Carrasco-Valiente J; Tena-Sempere M; Sarmento-Cabral A; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4956-e4968. PubMed ID: 34255835
[TBL] [Abstract][Full Text] [Related]
3. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
Luque RM; Sampedro-Nuñez M; Gahete MD; Ramos-Levi A; Ibáñez-Costa A; Rivero-Cortés E; Serrano-Somavilla A; Adrados M; Culler MD; Castaño JP; Marazuela M
Oncotarget; 2015 Aug; 6(23):19619-33. PubMed ID: 26124083
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
[TBL] [Abstract][Full Text] [Related]
5. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.
Rincón-Fernández D; Culler MD; Tsomaia N; Moreno-Bueno G; Luque RM; Gahete MD; Castaño JP
Carcinogenesis; 2018 Mar; 39(3):447-457. PubMed ID: 29272342
[TBL] [Abstract][Full Text] [Related]
6. In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.
Ibáñez-Costa A; Gahete MD; Rivero-Cortés E; Rincón-Fernández D; Nelson R; Beltrán M; de la Riva A; Japón MA; Venegas-Moreno E; Gálvez MÁ; García-Arnés JA; Soto-Moreno A; Morgan J; Tsomaia N; Culler MD; Dieguez C; Castaño JP; Luque RM
Sci Rep; 2015 Mar; 5():8714. PubMed ID: 25737012
[TBL] [Abstract][Full Text] [Related]
7. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
8. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.
Gahete MD; Córdoba-Chacón J; Hergueta-Redondo M; Martínez-Fuentes AJ; Kineman RD; Moreno-Bueno G; Luque RM; Castaño JP
PLoS One; 2011; 6(8):e23302. PubMed ID: 21829727
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
Hormaechea-Agulla D; Gómez-Gómez E; Ibáñez-Costa A; Carrasco-Valiente J; Rivero-Cortés E; L-López F; Pedraza-Arevalo S; Valero-Rosa J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Gahete MD; López-Miranda J; Requena MJ; Castaño JP; Luque RM
Cancer Lett; 2016 Dec; 383(1):125-134. PubMed ID: 27693462
[TBL] [Abstract][Full Text] [Related]
11. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
[TBL] [Abstract][Full Text] [Related]
13. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
[TBL] [Abstract][Full Text] [Related]
15. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
16. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.
Sáez-Martínez P; Jiménez-Vacas JM; León-González AJ; Herrero-Aguayo V; Montero Hidalgo AJ; Gómez-Gómez E; Sánchez-Sánchez R; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498336
[TBL] [Abstract][Full Text] [Related]
17. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
18. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
20. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.
Gómez-Gómez E; Jiménez-Vacas JM; Carrasco-Valiente J; Herrero-Aguayo V; Blanca-Pedregosa AM; León-González AJ; Valero-Rosa J; Fernández-Rueda JL; González-Serrano T; López-Miranda J; Gahete MD; Castaño JP; Requena-Tapia MJ; Luque RM
J Cell Mol Med; 2018 Nov; 22(11):5688-5697. PubMed ID: 30256519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
